Per Pfeiffer

Medicine & Life Sciences

1. Adenocarcinoma 18%
2. Adjuvant Chemotherapy 7%
3. Aerosols 26%
4. Bevacizumab 18%
5. Biomarkers 10%
6. C-Reactive Protein 5%
7. Capecitabine 21%
8. Carcinoembryonic Antigen 5%
9. Cell-Free Nucleic Acids 7%
10. Cetuximab 42%
11. Cisplatin 6%
12. Colonic Neoplasms 5%
13. Colorectal Neoplasms 100%
14. Combination Drug Therapy 10%
15. Confidence Intervals 6%
16. Denmark 9%
17. Drug Therapy 38%
18. Elderly 6%
19. encorafenib 5%
20. Epirubicin 8%
21. ErbB Receptors 6%
22. Esophageal Neoplasms 6%
23. Fluorouracil 26%
24. Gastrointestinal Neoplasms 10%
25. gemcitabine 8%
26. Geriatric Assessment 6%
27. Interleukin-6 5%
28. Irinotecan 36%
29. Leucovorin 12%
30. MicroRNAs 6%
31. Mutation 13%
32. N,N'-bis(pyridoxal-5-phosphate)ethylenediamine-N,N'-diacetic acid 5%
33. Neoplasm Metastasis 17%
34. Neoplasms 24%
35. Oxaliplatin 68%
36. Pancreatic Neoplasms 35%
37. pembrolizumab 8%
38. Population 10%
39. Progression-Free Survival 14%
40. Quality of Life 7%
41. Radiotherapy 9%
42. Randomized Controlled Trials 5%
43. Rectal Neoplasms 17%
44. S 1 (combination) 5%
45. Safety 7%
46. Stomach Neoplasms 9%
47. Survival 41%
48. Therapeutics 23%
49. trifluridine tipiracil 13%
50. XELOX 9%